RANK/RANKL Antagonists (Fulcrum Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameRANK/RANKL Antagonists (Fulcrum Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFulcrum Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFulcrum Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsOsteoporosis

Other Information

ATC CodeN/A
Related LinksN/A